Dysplasia and Colorectal Cancer Surveillance in Ulcerative Colitis Patients in Latin America: Real-World Data

被引:0
|
作者
Parra-Izquierdo, Viviana [1 ,2 ]
Otero-Regino, William [3 ,4 ,5 ]
Juliao-Banos, Fabian [6 ]
Frias-Ordonez, Juan Sebastian [3 ,4 ]
Ibanez-Pinilla, Edgar [7 ]
Gil-Parada, Fabio Leonel [8 ]
Marulanda-Fernandez, Hernando [3 ,4 ,5 ,9 ]
Otero-Parra, Lina [3 ,5 ]
Otero-Ramos, Elder [5 ,9 ]
Puentes-Manosalva, Fabian Eduardo [10 ]
Rojas, Gerardo Andres Guzman [11 ,12 ]
Ernest-Suarez, Kenneth [13 ,14 ]
Villa-Ovalles, Keyla [15 ]
Paredes-Mendez, Juan Eloy [16 ,17 ]
Jara-Alba, Maria Luisa [18 ]
Andrade-Zamora, David [19 ]
Ardila-Baez, Manuel Alonso [20 ]
Florez-Sarmiento, Cristian [2 ,21 ]
Veitia, Guillermo [22 ,23 ]
Sanchez, Abel [24 ]
Arango-Molano, Lazaro Antonio
Fluxa, Fernando [25 ]
Queiroz, Natalia Sousa Freitas [26 ]
Serrano, Mariastella [27 ]
机构
[1] Int Hosp Colombia, Gastroenterol & Rheumatol, Bucaramanga, Colombia
[2] Univ El Bosque, Cellular & Mol Immunol Grp INMUBO, Bogota, Colombia
[3] Univ Nacl Colombia, Gastroenterol, Bogota, Colombia
[4] Natl Univ Hosp Colombia, Gastroenterol & Digest Endoscopy, Bogota, Colombia
[5] Gastroenterol & Endoscopy Ctr, Gastroenterol & Digest Endoscopy, Bogota, Colombia
[6] Pablo Tobon Uribe Hosp, Gastroenterol, Medellin, Colombia
[7] El Bosque Univ, Fac Med, Bogota, Colombia
[8] Colombia Clin, Bogota, Colombia
[9] Cent Police Hosp, Bogota, Colombia
[10] Univ Caldas, Gastroenterol, Union Surg, ODO,Zentria Salud, Manizales, Caldas, Colombia
[11] Farallones Clin, Gastroenterol, Cali, Valle Del Cauca, Colombia
[12] Colsanitas Chipi Chape Med Ctr Cali, Gastroenterol, Valle Del Cauca, Colombia
[13] Univ Costa Rica, Sch Med, San Jose, Costa Rica
[14] Hosp Mexico, Inflammatory Bowel Dis Unit, Caja Costarricense Seguro Social, San Jose, Costa Rica
[15] Hosp Luis E Aybar, Gastroenterol & Digest Endoscopy, Santo Domingo, Dominican Rep
[16] Guillermo Almenara Natl Hosp, Gastroenterol, Lima, Peru
[17] Int Clin, Gastroenterol, Lima, Peru
[18] Teodoro Maldonado Carbo Specialty Hosp, Gastroenterol, Guayaquil, Ecuador
[19] Hosp Ecuadorian Inst Social Secur Cuenca, Gastroenterol, Cuenca, Ecuador
[20] Univ La Sabana, Gastroenterol, Chia, Colombia
[21] Hosp Int Colombia, Gastroenterol, Bucaramanga, Colombia
[22] Hosp Vargas Caracas, Gastroenterol, Caracas, Venezuela
[23] Univ Cent Venezuela, Gastroenterol, Caracas, Venezuela
[24] Roosevelt Hosp, Gastroenterol & Digest Endoscopy, Guatemala City, Guatemala
[25] Clin Meds, Gastroenterol, Santiago, Chile
[26] Pontificia Univ Catolica Parana PUCPR, Hlth Sci Grad Program, Curitiba, Brazil
[27] Georgetown Univ, Dept Pediat, Washington, DC USA
关键词
inflammatory bowel diseases; colonoscopy; colonic neoplasms; prognosis; colitis; ulcerative; INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; CHROMOENDOSCOPY; COLONOSCOPY; NEOPLASIA; EXPERIENCE; RISK; GASTROENTEROLOGY; MANAGEMENT; DIAGNOSIS;
D O I
10.1093/crocol/otae081
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The prevalence of colorectal cancer (CRC) in patients with ulcerative colitis (UC) is higher than in the general population, in Latin America there is a progressive increase of UC, and information about CRC screening in inflammatory bowel disease (IBD) is scarce. The aim of this study was to analyze the findings of endoscopic surveillance of CRC in patients with IBD according to available technology. Methods: Multicenter, cross-sectional, analytical study conducted in Latin American countries, in patients with UC, predominantly with more than 8 years of diagnosis and different degrees of disease activity. Surveillance colonoscopies were performed according to available technology. Risk factors for dysplasia detection were analyzed. Results: One hundred and forty-four patients, 55.5% women, mean age 47.3 (range 17.1 to 90; SD 15.64) years and mean duration of disease 12.71 (range 0.64 to 57.13; SD 8.08) years. Forty-nine lesions were identified, 18 corresponded to dysplasia. The detection rate of dysplasia per lesion and per procedure was 36.7% and 12.5%, respectively. By logistic regression analysis, the duration of disease (OR 1.12;95%CI:1.047 to 1.215, P = .002) and the presence of post-inflammatory polyps (OR 3.4;95%CI:1.11 to 10.36, P = .031) were risk factors for higher detection of dysplasia. Digital chromoendoscopy was associated with greater detection of dysplasia (OR 4.99, 95%CI: 1.092 to 22.864, P = .038). Conclusions: In our region, the duration of disease and the presence of post-inflammatory polyps were the factors with the highest association for dysplasia detection, and digital chromoendoscopy with directed biopsies was the technique of choice. The implementation of a specific surveillance program in colonoscopy in IBD is an effective strategy to achieve high detection rates.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Is Colorectal Cancer Surveillance Cost-Effective in Patients with Ulcerative Colitis?
    Onken, Jane E.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 : S196 - S197
  • [32] Surveillance for dysplasia is necessary for patients with ulcerative colitis - CON: Surveillance for ulcerative colitis-associated cancer: Time to change the endoscopy and the microscopy
    Shanahan, F
    Quera, R
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (09): : 1633 - 1636
  • [33] Surveillance for dysplasia is necessary for patients with ulcerative colitis - PRO: Endoscopic surveillance minimizes the risk of cancer
    Connell, W
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (09): : 1631 - 1633
  • [34] Safety of Upadacitinib in Older Patients With Ulcerative Colitis: A Real-World Experience
    Chowla, Navreet
    Tariq, Raseen
    Loftus, Edward
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S8 - S9
  • [35] Assessment of treatment sequence and real-world outcomes in patients with Ulcerative Colitis
    Chen, J.
    Zhao, Y.
    Liu, T.
    Candela, N.
    Lasch, K.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S466 - S467
  • [36] Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
    Lair-Mehiri, L.
    Stefanescu, C.
    Vaysse, T.
    Laharie, D.
    Roblin, X.
    Rosa, I.
    Treton, X.
    Abitbol, V.
    Amiot, A.
    Bouguen, G.
    Dib, N.
    Fumery, M.
    Pariente, B.
    Carbonnel, F.
    Peryn-Biroulet, L.
    Simon, M.
    Viennot, S.
    Bouhnik, Y.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S478 - S479
  • [37] Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
    Nakamura, S.
    Asano, T.
    Tanaka, Y.
    Sugimoto, K.
    Yoshigoe, S.
    Suzuki, Y.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I439 - I441
  • [38] Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
    Nakamura, S.
    Asano, T.
    Tanaka, Y.
    Sugimoto, K.
    Yoshigoe, S.
    Suzuki, Y.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I439 - I441
  • [39] A pilot study on the endoscopic surveillance of colorectal dysplasia and cancer in long-standing ulcerative colitis
    Mashhadi, SK
    Trapero, M
    Gisbert, JP
    Domínguez, EG
    Maté-Jiménez, J
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (01) : 16 - 23
  • [40] Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands
    Anne F van Rijn
    Paul Fockens
    Peter D Siersema
    Bas Oldenburg
    World Journal of Gastroenterology, 2009, 15 (02) : 226 - 230